Isoliquiritigenin是一种从甘草根中提取的抗肿瘤黄酮类化合物,以 320 nM 的 IC50 抑制醛糖还原酶,并以 24.7 μM 的 EC50 抑制流感病毒复制。
规格 | 价格 | 会员价 | 库存 | 数量 | |||
---|---|---|---|---|---|---|---|
{[ item.pr_size ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} | 现货 | 1周 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解
产品名称 | SIRT1 ↓ ↑ | SIRT2 ↓ ↑ | SIRT3 ↓ ↑ | SIRT5 ↓ ↑ | SIRT6 ↓ ↑ | SIRT7 ↓ ↑ | Sirtuin ↓ ↑ | 其他靶点 | 纯度 | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selisistat |
++++
SIRT1, IC50: 38 nM |
99%+ | |||||||||||||||||
Resveratrol | ✔ | 98% | |||||||||||||||||
Inauhzin | ✔ | p53 | 99%+ | ||||||||||||||||
Suramin sodium salt |
+++
SirT1, IC50: 297 nM |
++
SirT5, IC50: 22 μM |
99%+ | ||||||||||||||||
Salermide | ✔ | 99% | |||||||||||||||||
Quercetin Dihydrate | ✔ | 95% | |||||||||||||||||
Sirtinol |
+
SIRT1, IC50: 131 μM |
++
SIRT2, IC50: 38 μM |
98%+ | ||||||||||||||||
AGK2 |
+++
SIRT2, IC50: 3.5 μM |
99%+ | |||||||||||||||||
Tenovin-3 | ✔ | p53 | 99%+ | ||||||||||||||||
3-TYP |
++++
SIRT1, IC50: 88 nM |
++++
SIRT2, IC50: 92 nM |
++++
SIRT3, IC50: 16 nM |
95% | |||||||||||||||
Tenovin-6 |
++
SIRT1, IC50: 21 μM |
++
SIRT2, IC50: 10 μM |
+
SIRT3, IC50: 67 μM |
p53 | 99%+ | ||||||||||||||
SirReal2 |
+++
SIRT2, IC50: 140 nM |
99%+ | |||||||||||||||||
Thiomyristoyl |
++++
SIRT2, IC50: 28 nM |
99%+ | |||||||||||||||||
Et-29 | ✔ | 98% | |||||||||||||||||
OSS_128167 |
+
SIRT1, IC50: 1578 μM |
+
SIRT2, IC50: 751 μM |
+
SIRT6, IC50: 89 μM |
98% | |||||||||||||||
SIRT7 inhibitor 97491 |
+++
SIRT7, IC50: 325 nM |
97% | |||||||||||||||||
Nicotinamide | ✔ | 99+% | |||||||||||||||||
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 |
描述 | Isoliquiritigenin (ISL), a simple chalcone-type flavonoid, is derived from licorice compounds and is mainly present in foods, beverages, and tobacco[3]. Isoliquiritigenin inhibited rat lens aldose reductase with an IC50 of 3.2 x 10(-7) M, using DL-glyceraldehyde as a substrate. It inhibited sorbitol accumulation in human red blood cells, with an IC50 of 2.0 x 10(-6) M[4]. Isoliquiritigenin treatment markedly ameliorated cardiomyocytes contractile dysfunction caused by hypoxia. Moreover, Isoliquiritigenin reduced the mitochondrial potential (Δψ) of isolated mouse cardiomyocytes[3]. Isoliquiritigenin also showed the most potent inhibition of mouse rectal contraction induced by CCh(carbamylcholine) with an IC50 value of 1.70+/-0.07 microM[5]. |
Concentration | Treated Time | Description | References | |
NOZ cells | 0–100 mM | 24 hours, 48 hours, 72 hours | ISL significantly inhibited the proliferation of NOZ cells, with IC50 values of 151.3 mmol/L at 24 h, 59.5 mmol/L at 48 h, and 54.2 mmol/L at 72 h. | Chin Med J (Engl). 2023 Sep 20;136(18):2210-2220. |
SGC-996 cells | 0–100 mM | 24 hours, 48 hours, 72 hours | ISL significantly inhibited the proliferation of SGC-996 cells, with IC50 values of 210.1 mmol/L at 24 h, 72.9 mmol/L at 48 h, and 51.9 mmol/L at 72 h. | Chin Med J (Engl). 2023 Sep 20;136(18):2210-2220. |
HiBECs cells | 50 mM, 70 mM | 48 hours | ISL at 50 mmol/L and 70 mmol/L did not significantly alter the growth of HiBECs cells. | Chin Med J (Engl). 2023 Sep 20;136(18):2210-2220. |
L-2F7 cells | 50 mM, 70 mM | 48 hours | ISL at 50 mmol/L and 70 mmol/L did not significantly alter the growth of L-2F7 cells. | Chin Med J (Engl). 2023 Sep 20;136(18):2210-2220. |
U87 cells | 5 µM | 48 hours | To investigate the effects of ISL on circRNA expression, it was found that ISL significantly downregulated circ0030018 expression | MedComm (2020). 2023 May 26;4(3):e282. |
SHG44 cells | 5 µM | 48 hours | To investigate the effects of ISL on circ0030018 expression, it was found that ISL significantly downregulated circ0030018 expression | MedComm (2020). 2023 May 26;4(3):e282. |
Mouse primary bone marrow-derived macrophages (BMMs) | 16 or 64 μg/mL | 5 days | MSNs-ISL significantly inhibited RANKL-induced osteoclast generation, decreased the size and quantity of sealing zones, and reduced the osteolytic capacity of osteoclasts in vitro. | Theranostics. 2019 Jul 9;9(18):5183-5199. |
Administration | Dosage | Frequency | Description | References | ||
C57/BL6 mice | LPS-mediated calvarial bone erosion model | Subcutaneous injection | 50 mg/kg | Once every 2 days for 7 days | MSNs-ISL could block osteoclast activity, relieve inflammation-related calvarial bone destruction in vivo, and suppress c-Fos, NFATc1, and cathepsin K expression levels. | Theranostics. 2019 Jul 9;9(18):5183-5199. |
BALB/c Nude mice | NOZ cell xenograft model | Gavage | 50 mg/kg | Every 2 days for 28 days | ISL significantly inhibited tumor growth in the NOZ cell xenograft model, reducing tumor volume to less than 10% of the control group. HMOX1-deficient or GPX4-overexpressing NOZ cells partially reversed the inhibitory effect of ISL. | Chin Med J (Engl). 2023 Sep 20;136(18):2210-2220. |
计算器 | ||||
存储液制备 | ![]() |
1mg | 5mg | 10mg |
1 mM 5 mM 10 mM |
3.90mL 0.78mL 0.39mL |
19.51mL 3.90mL 1.95mL |
39.02mL 7.80mL 3.90mL |
CAS号 | 961-29-5 |
分子式 | C15H12O4 |
分子量 | 256.25 |
SMILES Code | O=C(C1=CC=C(O)C=C1O)/C=C/C2=CC=C(O)C=C2 |
MDL No. | MFCD00075907 |
别名 | GU17; ISL; GU 17, Isoliquiritigenin; 4,2',4'-Trihydroxychalcone; ILQ; SJ000286237; Isoliquiritigen |
运输 | 蓝冰 |
InChI Key | DXDRHHKMWQZJHT-FPYGCLRLSA-N |
Pubchem ID | 638278 |
存储条件 |
In solvent -20°C: 3-6个月 -80°C: 12个月 Pure form Keep in dark place, inert atmosphere, 2-8°C |
溶解方案 |
DMSO: 105 mg/mL(409.75 mM),注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO 无水乙醇: 100 mg/mL(390.24 mM),配合低频超声助溶,注意:无水乙醇开封后,易挥发,也会吸收空气中的水分,导致溶解能力下降,请避免使用开封较久的乙醇 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
|